Faricimab

Podcast

Podcast Episode 7: Exploring the Faricimab trials

In this episode, we examine the results and implications of the research in an expert discussion chaired by Prof Anat Loewenstein and Prof Reinier Schlingemann.

2021 Abstracts

Role of Dual Inhibition of Ang-2 and VEGF-A in Patients with Macular Edema Due to Branch or Central/Hemiretinal Retinal Vein Occlusion: Rationale and Design of the Faricimab Phase 3 BALATON and COMINO Trials

Author: Lars Hattenbach (Germany)

Co-authors: Nitin Jain, Arshard M. Khanani, Anat Lowenstein, Andras Seres, Ramin Tadayoni, Francis Abreu

Free Paper Session 6: Diabetes & Vascular Disease II – Personalised Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema

Free Paper Session 6: Diabetes & Vascular Disease II – Angiopoietin-2 Signalling and Vascular Stability With Faricimab in Diabetic Macular Edema

Free Paper Session 6: Diabetes & Vascular Disease II – VOYAGER: An Innovative, Global, Observational Study to Gain Real-world Insights Into the Long-term Utilisation of the Port Delivery System With Ranibizumab and Faricimab for the Treatment of nAMD and DME

Podcast Episode 7: Exploring the Faricimab trials

Prize Papers 1: AMD I – Efficacy, safety and durability of Faricimab in neovascular age-related macular degeneration: Week 48 results from the phase 3 TENAYA and LUCERNE trials

Prize Papers 2: Vascular Diseases & Diabetic Retinopathy I – Design and Rationale of the YOSEMITE and RHINE Trials: Two Phase 3 Studies of Faricimab in Patients With Diabetic Macular Edema

Prize Papers 2: Vascular Diseases & Diabetic Retinopathy I – Exploring Ang-2 Signalling in Vascular Stability in Patients With DME Receiving Faricimab in Phase 2 and Phase 3 Trials

Prize Papers 7: Vascular Diseases & Diabetic Retinopathy II – Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema: One-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Prize Papers 12: Vascular Diseases & Diabetic Retinopathy III – Faricimab Personalised Treatment Interval (PTI) Dosing Dynamics Illustrated With Patient Case Profiles: YOSEMITE and RHINE Phase 3 Diabetic Macular Edema (DME) Trials

Prize Papers 16: AMD IV – Design and rationale of the TENAYA and LUCERNE trials: 2 phase 3 studies of Faricimab, a dual Angiopoietin-2 and VEGF-A inhibitor, in patients with neovascular age-related macular degeneration

Role of Dual Inhibition of Ang-2 and VEGF-A in Patients with Macular Edema Due to Branch or Central/Hemiretinal Retinal Vein Occlusion: Rationale and Design of the Faricimab Phase 3 BALATON and COMINO Trials